Impact  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
regular  ||| S:10 E:18 ||| JJ
aspirin  ||| S:18 E:26 ||| JJ
use  ||| S:26 E:30 ||| NN
on  ||| S:30 E:33 ||| IN
overall  ||| S:33 E:41 ||| JJ
and  ||| S:41 E:45 ||| CC
cancer-specific  ||| S:45 E:61 ||| JJ
survival  ||| S:61 E:70 ||| NN
in  ||| S:70 E:73 ||| IN
patients  ||| S:73 E:82 ||| NNS
with  ||| S:82 E:87 ||| IN
colorectal  ||| S:87 E:98 ||| JJ
cancer  ||| S:98 E:105 ||| NN
harboring  ||| S:105 E:115 ||| VBG
a  ||| S:115 E:117 ||| DT
PIK3CA  ||| S:117 E:124 ||| JJ
mutation  ||| S:124 E:133 ||| JJ
Recent  ||| S:133 E:140 ||| JJ
data  ||| S:140 E:145 ||| NNS
have  ||| S:145 E:150 ||| VBP
suggested  ||| S:150 E:160 ||| VBN
that  ||| S:160 E:165 ||| IN
regular  ||| S:165 E:173 ||| JJ
aspirin  ||| S:173 E:181 ||| JJ
use  ||| S:181 E:185 ||| NN
improves  ||| S:185 E:194 ||| VBZ
overall  ||| S:194 E:202 ||| JJ
and  ||| S:202 E:206 ||| CC
cancer-specific  ||| S:206 E:222 ||| JJ
survival  ||| S:222 E:231 ||| NN
in  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
subset  ||| S:238 E:245 ||| NN
of  ||| S:245 E:248 ||| IN
colorectal  ||| S:248 E:259 ||| JJ
cancer  ||| S:259 E:266 ||| NN
( ||| S:266 E:267 ||| -LRB-
CRC ||| S:267 E:270 ||| NNP
)  ||| S:270 E:272 ||| -RRB-
patients  ||| S:272 E:281 ||| FW
harboring  ||| S:281 E:291 ||| FW
PIK3CA  ||| S:291 E:298 ||| FW
mutations ||| S:298 E:307 ||| FW
.  ||| S:307 E:309 ||| .
However ||| S:309 E:316 ||| RB
,  ||| S:316 E:318 ||| ,
the  ||| S:318 E:322 ||| DT
number  ||| S:322 E:329 ||| NN
of  ||| S:329 E:332 ||| IN
PIK3CA-mutated  ||| S:332 E:347 ||| NNP
CRC  ||| S:347 E:351 ||| NNP
patients  ||| S:351 E:360 ||| NNS
examined  ||| S:360 E:369 ||| VBN
in  ||| S:369 E:372 ||| IN
these  ||| S:372 E:378 ||| DT
studies  ||| S:378 E:386 ||| NNS
was  ||| S:386 E:390 ||| VBD
modest ||| S:390 E:396 ||| JJ
.  ||| S:396 E:398 ||| .
Our  ||| S:398 E:402 ||| PRP$
collaborative  ||| S:402 E:416 ||| JJ
study  ||| S:416 E:422 ||| NN
aims  ||| S:422 E:427 ||| VBZ
to  ||| S:427 E:430 ||| TO
validate  ||| S:430 E:439 ||| VB
the  ||| S:439 E:443 ||| DT
association  ||| S:443 E:455 ||| NN
between  ||| S:455 E:463 ||| IN
regular  ||| S:463 E:471 ||| JJ
aspirin  ||| S:471 E:479 ||| JJ
use  ||| S:479 E:483 ||| NN
and  ||| S:483 E:487 ||| CC
survival  ||| S:487 E:496 ||| NN
in  ||| S:496 E:499 ||| IN
patients  ||| S:499 E:508 ||| NNS
with  ||| S:508 E:513 ||| IN
PIK3CA-mutated  ||| S:513 E:528 ||| NNP
CRC ||| S:528 E:531 ||| NNP
.  ||| S:531 E:533 ||| .
Patients  ||| S:533 E:542 ||| NNS
with  ||| S:542 E:547 ||| IN
PIK3CA-mutated  ||| S:547 E:562 ||| NNP
CRC  ||| S:562 E:566 ||| NNP
were  ||| S:566 E:571 ||| VBD
identified  ||| S:571 E:582 ||| VBN
at  ||| S:582 E:585 ||| IN
Moffitt  ||| S:585 E:593 ||| NNP
Cancer  ||| S:593 E:600 ||| NNP
Center  ||| S:600 E:607 ||| NNP
( ||| S:607 E:608 ||| -LRB-
MCC ||| S:608 E:611 ||| NNP
)  ||| S:611 E:613 ||| -RRB-
in  ||| S:613 E:616 ||| IN
the  ||| S:616 E:620 ||| DT
United  ||| S:620 E:627 ||| NNP
States  ||| S:627 E:634 ||| NNPS
and  ||| S:634 E:638 ||| CC
Royal  ||| S:638 E:644 ||| NNP
Melbourne  ||| S:644 E:654 ||| NNP
Hospital  ||| S:654 E:663 ||| NNP
( ||| S:663 E:664 ||| -LRB-
RMH ||| S:664 E:667 ||| NNP
)  ||| S:667 E:669 ||| -RRB-
in  ||| S:669 E:672 ||| IN
Australia ||| S:672 E:681 ||| NNP
.  ||| S:681 E:683 ||| .
Prospective  ||| S:683 E:695 ||| JJ
clinicopathological  ||| S:695 E:715 ||| JJ
data  ||| S:715 E:720 ||| NNS
and  ||| S:720 E:724 ||| CC
survival  ||| S:724 E:733 ||| NN
data  ||| S:733 E:738 ||| NNS
were  ||| S:738 E:743 ||| VBD
available ||| S:743 E:752 ||| JJ
.  ||| S:752 E:754 ||| .
At  ||| S:754 E:757 ||| IN
MCC ||| S:757 E:760 ||| NNP
,  ||| S:760 E:762 ||| ,
PIK3CA  ||| S:762 E:769 ||| CD
mutations  ||| S:769 E:779 ||| NNS
were  ||| S:779 E:784 ||| VBD
identified  ||| S:784 E:795 ||| VBN
by  ||| S:795 E:798 ||| IN
targeted  ||| S:798 E:807 ||| JJ
exome  ||| S:807 E:813 ||| NNS
sequencing  ||| S:813 E:824 ||| VBP
using  ||| S:824 E:830 ||| VBG
the  ||| S:830 E:834 ||| DT
Illumina  ||| S:834 E:843 ||| NNP
GAIIx  ||| S:843 E:849 ||| NNP
Next  ||| S:849 E:854 ||| NNP
Generation  ||| S:854 E:865 ||| NNP
Sequencing  ||| S:865 E:876 ||| NNP
platform ||| S:876 E:884 ||| NN
.  ||| S:884 E:886 ||| .
At  ||| S:886 E:889 ||| IN
RMH ||| S:889 E:892 ||| NNP
,  ||| S:892 E:894 ||| ,
Sanger  ||| S:894 E:901 ||| NNP
sequencing  ||| S:901 E:912 ||| NN
was  ||| S:912 E:916 ||| VBD
utilized ||| S:916 E:924 ||| VBN
.  ||| S:924 E:926 ||| .
Multivariate  ||| S:926 E:939 ||| JJ
survival  ||| S:939 E:948 ||| NN
analyses  ||| S:948 E:957 ||| NNS
were  ||| S:957 E:962 ||| VBD
conducted  ||| S:962 E:972 ||| VBN
using  ||| S:972 E:978 ||| VBG
Cox  ||| S:978 E:982 ||| NNP
logistic  ||| S:982 E:991 ||| FW
regression ||| S:991 E:1001 ||| FW
.  ||| S:1001 E:1003 ||| .
From  ||| S:1003 E:1008 ||| IN
a  ||| S:1008 E:1010 ||| DT
cohort  ||| S:1010 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
1487  ||| S:1020 E:1025 ||| CD
CRC  ||| S:1025 E:1029 ||| NN
patients ||| S:1029 E:1037 ||| NNS
,  ||| S:1037 E:1039 ||| ,
185  ||| S:1039 E:1043 ||| CD
patients  ||| S:1043 E:1052 ||| NNS
harbored  ||| S:1052 E:1061 ||| VBP
a  ||| S:1061 E:1063 ||| DT
PIK3CA  ||| S:1063 E:1070 ||| JJ
mutation ||| S:1070 E:1078 ||| NN
.  ||| S:1078 E:1080 ||| .
Median  ||| S:1080 E:1087 ||| JJ
age  ||| S:1087 E:1091 ||| NN
of  ||| S:1091 E:1094 ||| IN
patients  ||| S:1094 E:1103 ||| NNS
with  ||| S:1103 E:1108 ||| IN
PIK3CA-mutated  ||| S:1108 E:1123 ||| CD
tumors  ||| S:1123 E:1130 ||| NNS
was  ||| S:1130 E:1134 ||| VBD
72  ||| S:1134 E:1137 ||| CD
years  ||| S:1137 E:1143 ||| NNS
( ||| S:1143 E:1144 ||| -LRB-
range ||| S:1144 E:1149 ||| NN
:  ||| S:1149 E:1151 ||| :
34-92 ||| S:1151 E:1156 ||| CD
)  ||| S:1156 E:1158 ||| -RRB-
and  ||| S:1158 E:1162 ||| CC
median  ||| S:1162 E:1169 ||| NNS
follow  ||| S:1169 E:1176 ||| VBP
up  ||| S:1176 E:1179 ||| RB
was  ||| S:1179 E:1183 ||| VBD
54  ||| S:1183 E:1186 ||| CD
months ||| S:1186 E:1192 ||| NNS
.  ||| S:1192 E:1194 ||| .
Forty-nine  ||| S:1194 E:1205 ||| NNP
( ||| S:1205 E:1206 ||| -LRB-
26 ||| S:1206 E:1208 ||| CD
% ||| S:1208 E:1209 ||| NN
)  ||| S:1209 E:1211 ||| -RRB-
patients  ||| S:1211 E:1220 ||| NNS
used  ||| S:1220 E:1225 ||| VBD
aspirin  ||| S:1225 E:1233 ||| VBN
regularly ||| S:1233 E:1242 ||| RB
.  ||| S:1242 E:1244 ||| .
Regular  ||| S:1244 E:1252 ||| JJ
aspirin  ||| S:1252 E:1260 ||| JJ
use  ||| S:1260 E:1264 ||| NN
was  ||| S:1264 E:1268 ||| VBD
not  ||| S:1268 E:1272 ||| RB
associated  ||| S:1272 E:1283 ||| VBN
with  ||| S:1283 E:1288 ||| IN
improved  ||| S:1288 E:1297 ||| JJ
overall  ||| S:1297 E:1305 ||| JJ
survival  ||| S:1305 E:1314 ||| NN
( ||| S:1314 E:1315 ||| -LRB-
multivariate  ||| S:1315 E:1328 ||| FW
HR  ||| S:1328 E:1331 ||| FW
0.96 ||| S:1331 E:1335 ||| FW
,  ||| S:1335 E:1337 ||| ,
p  ||| S:1337 E:1339 ||| VBG
=  ||| S:1339 E:1341 ||| SYM
0.86 ||| S:1341 E:1345 ||| CD
) ||| S:1345 E:1346 ||| -RRB-
.  ||| S:1346 E:1348 ||| .
There  ||| S:1348 E:1354 ||| EX
was  ||| S:1354 E:1358 ||| VBD
a  ||| S:1358 E:1360 ||| DT
trend  ||| S:1360 E:1366 ||| NN
towards  ||| S:1366 E:1374 ||| IN
improved  ||| S:1374 E:1383 ||| JJ
cancer-specific  ||| S:1383 E:1399 ||| JJ
survival  ||| S:1399 E:1408 ||| NN
( ||| S:1408 E:1409 ||| -LRB-
multivariate  ||| S:1409 E:1422 ||| FW
HR  ||| S:1422 E:1425 ||| NNP
0.60 ||| S:1425 E:1429 ||| CD
,  ||| S:1429 E:1431 ||| ,
p  ||| S:1431 E:1433 ||| VBG
=  ||| S:1433 E:1435 ||| SYM
0.14 ||| S:1435 E:1439 ||| CD
) ||| S:1439 E:1440 ||| -RRB-
,  ||| S:1440 E:1442 ||| ,
but  ||| S:1442 E:1446 ||| CC
this  ||| S:1446 E:1451 ||| DT
was  ||| S:1451 E:1455 ||| VBD
not  ||| S:1455 E:1459 ||| RB
significant ||| S:1459 E:1470 ||| JJ
.  ||| S:1470 E:1472 ||| .
Despite  ||| S:1472 E:1480 ||| IN
examining  ||| S:1480 E:1490 ||| VBG
a  ||| S:1490 E:1492 ||| DT
large  ||| S:1492 E:1498 ||| JJ
number  ||| S:1498 E:1505 ||| NN
of  ||| S:1505 E:1508 ||| IN
patients ||| S:1508 E:1516 ||| NNS
,  ||| S:1516 E:1518 ||| ,
we  ||| S:1518 E:1521 ||| PRP
did  ||| S:1521 E:1525 ||| VBD
not  ||| S:1525 E:1529 ||| RB
confirm  ||| S:1529 E:1537 ||| VB
that  ||| S:1537 E:1542 ||| DT
regular  ||| S:1542 E:1550 ||| JJ
aspirin  ||| S:1550 E:1558 ||| JJ
use  ||| S:1558 E:1562 ||| NN
was  ||| S:1562 E:1566 ||| VBD
associated  ||| S:1566 E:1577 ||| VBN
with  ||| S:1577 E:1582 ||| IN
statistically  ||| S:1582 E:1596 ||| JJ
significant  ||| S:1596 E:1608 ||| JJ
improvements  ||| S:1608 E:1621 ||| NNS
in  ||| S:1621 E:1624 ||| IN
survival  ||| S:1624 E:1633 ||| NN
in  ||| S:1633 E:1636 ||| IN
PIK3CA-mutated  ||| S:1636 E:1651 ||| NNP
CRC  ||| S:1651 E:1655 ||| NNP
patients ||| S:1655 E:1663 ||| NNS
.  ||| S:1663 E:1665 ||| .
Prospective  ||| S:1665 E:1677 ||| JJ
evaluation  ||| S:1677 E:1688 ||| NN
of  ||| S:1688 E:1691 ||| IN
this  ||| S:1691 E:1696 ||| DT
relationship  ||| S:1696 E:1709 ||| NN
is  ||| S:1709 E:1712 ||| VBZ
warranted ||| S:1712 E:1721 ||| VBN
.  ||| S:1721 E:1723 ||| .
